Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...
Nasdaq13d
INDUS Group Expands Portfolio With Acquisition Of Sweden's ELECTRO TRADING
Headquartered in Bromma near Stockholm, with an additional location ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in ...
IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 ...
IRLAB Therapeutics: IRLAB Strengthens Its Value Creation Capabilities Through Extended And Expanded Debt Financing
GOTHENBURG, SWEDEN / ACCESS Newswire / February 17, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)/ IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel trea ...
Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface
Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacterial growth on the company’s implant ...